SoyCap and osteoporosis in postmenopausal In recent years, alternative osteoporosis from menopause was the use of isoflavones from soya derivari also own some recent studies have shown conflicting data on the usefulness of these substances in effectively counter the loss of bone mass in menopause. Some research has shown that the potential benefit expressed by isoflavones is due to the individual's ability to metabolize daidzein (isoflavone of the soy plant complex) in equol. The process of metabolization in equol takes place in the colon by means of the intestinal bacterial flora, the equol once absorbed would show estrogenic activity four times greater than the daidzein. The studies lead us back to two different phenotypes where one shows a intestinal bacterial flora able to modify the daizdeina in equol and then to demonstrate the protective effect on the loss of bone mass, but the other does not have a favorable bacterial flora to the transformation of daizdeina in equol and therefore fails to benefit the desired effect. This would assume that efficient bacterial flora may be useful to support the metabolism of equol in daizdeina and promote estrogenic activity by counteracting the loss of bone mass during menopause. The conflicting data can be highlighted in recent scientific publications where Chinese researchers in ten different studies which was attended by 608 people with obvious benefits on bone mass after taking 90 mg / day of soy isoflavones for six months. Another study published in the Netherlands to 237 women in post-menopausal administration of fortified foods in soy isoflavones (110 mg / day) have instead produced substantial changes to bone mass. How to use recommended one capsule once a day *. * Equivalent to 80 mg / day of isoflavones.
